CLINICAL TRIALS PROFILE FOR CAMPRAL
✉ Email this page to a colleague
All Clinical Trials for CAMPRAL
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00006206 ↗ | COMBINE (Acamprosate/Naltrexone) | Completed | Lipha Pharmaceuticals | Phase 3 | 1997-08-01 | Combine is a multicenter, randomized clinical trial that will evaluate combinations of three interventions for treating alcohol dependence. The goal is to determine whether improvement in treatment outcomes can be achieved by various combinations of drug and behavioral interventions. Two of the interventions will consist of pharmacological treatment with naltrexone (Revia) or acamprosate (Campral). The third intervention is a multicomponent behavioral therapy including such components as motivational enhancement therapy, cognitive behavioral therapy, and referral to self-help groups, including AA. All three interventions will include a component supporting compliance to medications and reduction in drinking. |
NCT00006206 ↗ | COMBINE (Acamprosate/Naltrexone) | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 3 | 1997-08-01 | Combine is a multicenter, randomized clinical trial that will evaluate combinations of three interventions for treating alcohol dependence. The goal is to determine whether improvement in treatment outcomes can be achieved by various combinations of drug and behavioral interventions. Two of the interventions will consist of pharmacological treatment with naltrexone (Revia) or acamprosate (Campral). The third intervention is a multicomponent behavioral therapy including such components as motivational enhancement therapy, cognitive behavioral therapy, and referral to self-help groups, including AA. All three interventions will include a component supporting compliance to medications and reduction in drinking. |
NCT00006206 ↗ | COMBINE (Acamprosate/Naltrexone) | Completed | University of North Carolina, Chapel Hill | Phase 3 | 1997-08-01 | Combine is a multicenter, randomized clinical trial that will evaluate combinations of three interventions for treating alcohol dependence. The goal is to determine whether improvement in treatment outcomes can be achieved by various combinations of drug and behavioral interventions. Two of the interventions will consist of pharmacological treatment with naltrexone (Revia) or acamprosate (Campral). The third intervention is a multicomponent behavioral therapy including such components as motivational enhancement therapy, cognitive behavioral therapy, and referral to self-help groups, including AA. All three interventions will include a component supporting compliance to medications and reduction in drinking. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CAMPRAL
Condition Name
Clinical Trial Locations for CAMPRAL
Trials by Country
Clinical Trial Progress for CAMPRAL
Clinical Trial Phase
Clinical Trial Sponsors for CAMPRAL
Sponsor Name